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Abstract TP53 is a key tumor suppressor gene that encodes a transcriptional factor involved in several
cellular mechanisms, including growth arrest, DNA repair, and induction of apoptosis. In addition
to TP53 gene mutations, a common polymorphism, Arg72Pro, has been involved in the carcinogen-
esis process. The Pro72 variant has been associated with a slower induction of apoptosis and may
influence the risk of cancer development. The role of Arg72Pro polymorphism in glioma suscepti-
bility is poorly characterized. With the objective of analyzing the role of the TP53 Arg72Pro poly-
morphism in glioma risk, overall survival, and patient therapy response in a Portuguese population,
we conducted a retrospective caseecontrol study, including 171 patients with gliomas and 526 can-
cer-free individuals. The Arg72Pro genotype was assessed by the polymerase chain reactione
restriction fragment length polymorphism technique. No statistically significant differences were
observed in the genotypic and allelic frequencies between glioma and control groups, and no sta-
tistically significant differences were observed with stratification of gliomas into distinct histolog-
ical subtypes: astrocytic (n 5 115), glioblastoma (n 5 75), and oligodendroglial (n 5 54) tumors.
No significant association was observed between TP53 Arg72Pro and patient overall survival, but
KaplaneMeier analysis of glioma patients harboring the Pro72 allele showed a significantly longer
survival with adjuvant therapy. In this first assessment of the role of TP53 Arg72Pro polymorphism
in a large series of Portuguese glioma tumors, no association was observed with glioma suscepti-
bility or overall survival, except for patients submitted to adjuvant therapy.  2008 Elsevier Inc.
All rights reserved.1. Introduction
Central nervous system tumors correspond to !2% of
adult tumors, but they are the second most common among
pediatric tumors [1,2]. These tumors are an important cause
of morbidity and mortality, being the first leading cause of
cancer-related death in childhood and the fourth among
middle aged-men [1,2]. In Portugal, the incidence of central
nervous system tumors is similar to that in other European
countries [3].
* Corresponding author. Tel.: þ351-235-604825; fax: þ351-253-
604820.
E-mail address: rreis@ecsaude.uminho.pt (R.M. Reis).
1 These authors contributed equally to the present study.0165-4608/08/$ e see front matter  2008 Elsevier Inc. All rights reserved.
doi:10.1016/j.cancergencyto.2007.08.019Gliomas are the most common group of brain tumors;
astrocytic tumors are the main histological type, followed
by oligodendroglial and mixed oligoastrocytic tumors. Gli-
omas are classified into four grades of malignancy, accord-
ing to the World Health Organization (WHO) classification
[1]. Glioblastoma (WHO grade IV), the most malignant and
frequent adult histological type, can be clinically and genet-
ically subdivided into primary or de novo and secondary
glioblastoma [1,4,5]. Primary glioblastomas correspond to
~95% of the cases, evolve rapidly without any evidence
of a less malignant precursor lesion, and are characterized
by EGFR amplification or overexpression [1,4,5]. Second-
ary glioblastomas develop more slowly, through progres-
sion of a less malignant lesion, and molecularly exhibit
TP53 mutations and PDGFR overexpression [1,4,5]. With
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prognosis of glioma patients remains poor, especially in
glioblastomas, with a mean survival time of ~1 year and
an overall 5-year survival rate of !2% [1].
Little is known about the etiological factors of gliomas
[6]. Several exogenous factors have been reported, such
as the use of cell phones, exposure to high-tension wires,
head trauma, and N-nitroso compounds, only ionizing
radiation has been unequivocally implicated in glioma risk
[6]. Genetically, only a small proportion of gliomas occur
in a context of a familial cancer syndrome due to inherited
high-penetrance mutations, such as LieFraumeni syn-
drome (TP53 germline mutation), neurofibromatosis 1
syndrome (NF1 germline mutation), neurofibromatosis 2
syndrome (NF2 germline mutation), and Turcot syndrome
(MLH1 or PMS2 and APC germline mutation) [1]. The
great majority of gliomas arise sporadically, and current
evidence suggests that low-penetrance genetic polymor-
phisms can play a role in susceptibility to sporadic tumors
[7]. Polymorphisms of genes involved in DNA repair, cell
cycle control, carcinogen metabolism, or immune response
have been associated with higher susceptibility to glioma
development, but without consistent findings [7].
The TP53 tumor suppressor gene encodes a transcrip-
tional factor, p53, which is involved in a diversity of cellular
processes, including growth arrest, induction of apoptosis,
DNA repair, and inhibition of angiogenesis [8]. The p53 pro-
tein is activated in response to various genotoxic and nonge-
notoxic stimulus, triggering the expression of several genes
that affect cell cycle arrest (via the p21 pathway) and DNA
repair (via the GADD45 pathway). If repair fails, apoptosis
is triggered (via the bax pathway), hence, the denomination
of p53 as the ‘‘genome guardian’’ [9]. Inactivation of TP53
by somatic mutations is a key molecular event, detected in
~50% of all malignancies and in ~40% of gliomas [10].
Several studies have focused on TP53 polymorphisms as
predisposing factors for tumor development [11]. One such
polymorphism is the TP53 Arg72Pro, located in exon 4 at
codon 72, involving a guanine to cytosine nucleotide
exchange, which leads to nonconservative change of an
arginine to proline. This single-nucleotide polymorphism
is located in a proline-rich encoding region of TP53 gene,
which is important for growth suppression and apoptotic
function of p53 protein, indicating that Arg72 and Pro72
variants have distinct biochemical and biological activities
[11]. Arg72 is significantly more efficient than Pro72 in
apoptosis induction, and Pro72 individuals have been
shown to be at higher risk of develop cancer [12e18]. In
some epithelial cancers, the Pro72 variant was associated
with a worse survival than Arg72 [15,19]. On the other
hand, Pro72 is shown to be a stronger inducer of transcrip-
tion than Arg72 [12], and some studies suggest that Arg72
variant is more susceptible than Pro72 to degradation by
human papillomavirus E6 protein [20].
Few reports have addressed the association of Arg72Pro
polymorphism with susceptibility to glioma, and the resultsobtained are inconsistent [21e25]. Moreover, there are no
reports concerning the association between this polymor-
phism and glioma patient outcome or adjuvant therapy re-
sponse. Our objective was to determine whether TP53
Arg72Pro polymorphism represents a predisposition factor
for glioma risk and to identify the impact on patient sur-
vival and therapeutic response in a Portuguese population.
2. Materials and methods
2.1. Patient and control populations
In this retrospective analysis, tumor samples were
obtained from patients treated at Hospital S. Joa˜o, Porto,
and at Hospital S. Marcos, Braga, Portugal, as previously
described [26]. The study of Arg72Pro polymorphisms in-
cluded 171 patients with sporadic gliomas of distinct histo-
logical subtypes (Table 1) and 526 cancer-free individuals.
The cancer-free control group was randomly selected from
blood donors at Hospital S. Marcos, Bragal, and from Clı´ni-
ca Laboratorial and Dr. Edgar Botelho Moniz, Santo Tirso.
All patients and control subjects were from northwestern
Portugal and of European-origin ethnic background. The
mean age of the patient population was 49.5 years; the
mean age of the control group was 38.1 years. The distribu-
tion by sex of the patients was matched between patients
(52.6% male, 47.4% female) and the control group
(50.2% male, 49.8% female).
The procedures followed in the present study were in
accordance with the institutional ethical standards. All
samples enrolled in the present study were deidentified
and unlinked from their donors.
2.2. DNA preparation
Tumor DNA was obtained from paraffin-embedded sec-
tions, as previously described [26]. (For the great majority
of glioma patients, no peripheral blood DNA was avail-
able.) Briefly, paraffin was removed by incubation in
Table 1
Histological and clinical features of glioma patients
Tumor type
WHO
grade
Cases,
no.
Age, years,
mean 6 SD
Male/
female,
n/n
Astrocytic
Pilocytic astrocytoma I 6 24.8 6 7.1 2/4
Diffuse astrocytoma II 24 36.5 6 13.2 9/15
Anaplastic astrocytoma III 4 38.8 6 12.9 4/0
Glioblastomaa IV 75 57.2 6 12.3 40/35
Gliosarcoma IV 6 60.5 6 10.3 3/3
Oligodendroglial
Oligodendroglioma II 22 38.1 6 15.9 12/10
Anaplastic oligodendroglioma III 32 53.3 6 11.2 19/13
Oligoastrocytic
Oligoastrocytoma II 2 41.5 6 19.1 1/1
TOTAL 171 49.5 6 15.9 90/81
a All are primary de novo glioblastomas.
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in 100 mL of lysis buffer (500 mmol/L Tris-HCl, pH 8.5,
and 1 mmol/L EDTA, pH 8.0, containing proteinase K to
a final concentration of 0.5 mg/mL) at 55C for 48 hours.
After heat denaturation, DNA samples were stored at
e20C for subsequent molecular analysis. DNA of the
control population was extracted from peripheral blood
leukocytes according to the proteinase Kechloroforme
isopropanol protocol [27].
2.3. TP53 Arg72Pro genotyping analysis
Analysis of TP53 Arg72Pro polymorphism was per-
formed by polymerase chain reactionerestriction fragment
length polymorphism (PCR-RFLP). Briefly, amplification
reactionwas carried out in a total volume of 25mL, consisting
of 2 mL of DNA solution, 1 U TaqDNA polymerase (Bioron,
Ludwigshafen, Germany), 1.5 mmol/L MgCl2 (Bioron), 0.2
mmol/L of each dNTP (Fermentas, Burlington, ON, Cana-
da), 0.1 mmol/L of both sense and antisense primers, and
1 enzyme buffer (Bioron). PCR amplification was per-
formed in an Primus 96 Plus thermal cycler (MWG Biotech,
High Point, NC), with an initial denaturation step at 94C for
5 minutes, then amplified for 38 cycles of denaturation at
94C for 45 seconds, annealing at 55C for 45 seconds, exten-
sion at 72C for 45 seconds, and final extension step at 72C
for 10minutes. Primer sequenceswere: 50-CTGCCCTGGTA
GGTTTTCTG-30 (reverse) and 50-GAAGACCCAGGTCC
AGATGA-30 (forward), leading to a 152-bp PCR product.
The PCR product was then analyzed by RFLP. he DNA
PCR products were digested overnight at 37C with
Bsh1236I (Fermentas), according to the manufacturer’s in-
structions. The results of enzymatic digestion were visual-
ized in a 3% agarose gel by electrophoresis. The results
were the 152-bp fragment of uncut PCR product representing
homozygotes proline, two fragments of 50 and 102 bp repre-
senting homozygotes arginine, and three fragments of 50,
102, and 152 bp representing heterozygotes for codon 72.
2.4. Statistical analysis
Analysis of data was performed using the SPSS version
14.0 computer software (SPSS, Chicago, IL). Chi-square
analysis was used to compare categorical variables. A 5%
level of significance was used in the analysis. The odds ra-
tio (OR) and its 95% confidence interval (CI) were calcu-
lated to measure the association between TP53 Arg72Pro
polymorphism and glioma risk. Logistic regression analysis
was used to calculate the adjusted OR and 95% CI for the
influence of TP53 genotypes in the risk of glioma, adjusted
for age. Whenever appropriate, the observed number of
each genotype was compared with that expected for a pop-
ulation in the HardyeWeinberg equilibrium by using
a goodness of fit c2 test.
Survival and adjuvant treatment (radiotherapy and/or
chemotherapy) data was available for 117 of the 171patients. The probabilities of survival were calculated,
and the medians and life-tables were computed using the
productelimit estimate of KaplaneMeier. The curves were
examined by the log-rank test, a statistical test for equality
of survival distributions. Survival duration was defined as
the time between diagnosis and death or the time to the
most recent clinical evaluation of the patient.
3. Results
The frequencies of the Arg/Arg, Arg/Pro, and Pro/Pro
genotypes in the control group were 56.7%, 37.5% and
5.9%, respectively, resulting in a Pro allele frequency of
0.25. The distribution of these genotype frequencies was
in agreement with those calculated from the Hardye
Weinberg equilibrium model for controls (P 5 0.986).
The distribution of the three different TP53 codon 72 ge-
notypes (Arg/Arg, Arg/Pro, and Pro/Pro) in both groups
(cases and controls) is presented in Table 2. First, we com-
pared the distribution of the TP53 Arg72Pro genotypes in
glioma with the control group; no statistical difference
was found (P O 0.05). Likewise, the distribution of the
Pro allele variant between case and control groups was
not statistically different (P O 0.05) (Table 2).
We further stratified glioma cases by the histological sub-
types astrocytic (grade I, II, III, and IV), glioblastoma (grade
IV), and oligodendroglial (grade II and III) tumors and deter-
mined their genotype distribution. The genotype frequencies
of the three histological groupswere not statistically different
from that of the control group (PO 0.05) (Table 2), and no
statistical difference was found in the allelic distribution
(PO 0.05) of these groups. Assessment of other stratification
groupsddiffusely infiltrating astrocytic tumors (grade II, III,
IV), low-grade astrocytic tumors (grade I and II), and high-
grade astrocytic tumors (grade III and IV)drevealed no sig-
nificant differences (data not shown).
KaplaneMeier curves were performed, to evaluate the
possible association between the Arg72Pro polymorphism
and overall patient survival. No statistical difference was
observed (P O 0.05) for the gliomas (n 5 117) for either
5-year or 10-year analysis (Fig. 1). Likewise, no significant
associations were observed for the glioblastoma and oligo-
dendroglioma subtypes (data not shown).
We also assessed the role of the Arg72Pro polymorphism
with patient response to adjuvant treatment (radiotherapy or
chemotherapy or both; n 5 42). In the 5-year analysis, the
median survival time in months of gliomas in patients with
adjuvant therapy was 13 6 20.4 SD for the Arg/Arg geno-
type, 24 6 33.7 SD for the Arg/Pro genotype, and 57 6
30.2 SD for the Pro/Pro genotype. KaplaneMeier curves
showed a tendency of longer survival associatedwith patients
exhibiting Pro/Pro genotype (P 5 0.076) (data not shown)
and a significantly longer survival in patients harboring the
Pro allele (Arg/Pro þ Pro/Pro, P 5 0.027) (Fig. 2). Upon
histological stratification, only the oligodendroglioma
Table 2
Frequency of TP53 Arg72Pro genotypes in glioma patients and healthy individuals
Genotype
Group 1, controls Group 2, patients
P value OR (95% CI)No. % No. %
Gliomas
Arg/Arg 298 56.7 101 59.0 Ref.
Arg/Pro 197 37.5 56 32.7 0.355 0.84 (0.58e1.22)
Pro/Pro 31 5.9 14 8.2 0.400 1.33 (0.68e2.60)
0.580a 0.91 (0.64e1.29)a
0.289b 1.42 (0.74e2.74)b
Arg allele 793 75.4 258 75.0 Ref.
Pro allele 259 24.6 86 25.0 0.887 1.02 (0.76e1.37)
Astrocytomasc
Arg/Arg 298 56.7 70 60.9 Ref.
Arg/Pro 197 37.5 37 32.2 0.315 0.80 (0.52e1.24)
Pro/Pro 31 5.9 8 6.9 0.822 1.10 (0.48e2.49)
0.408a 0.84 (0.56e1.27)a
0.666b 1.19 (0.53e2.67)b
Arg allele 793 75.4 177 77.0 Ref.
Pro allele 259 24.6 53 23.0 0.614 0.92 (0.64e1.30)
Glioblastomas
Arg/Arg 298 56.7 47 62.7 Ref.
Arg/Pro 197 37.5 24 32.0 0.333 0.77 (0.46e1.30)
Pro/Pro 31 5.9 4 5.3 0.717 0.82 (0.28e2.42)
0.325a 0.78 (0.47e1.28)a
0.846b 0.90 (0.31e2.62)b
Arg allele 793 75.4 118 78.7 Ref.
Pro allele 259 24.6 32 21.3 0.379 0.83 (0.54e1.28)
Oligodendrogliomas
Arg/Arg 298 56.7 31 57.4 Ref.
Arg/Pro 197 37.5 18 33.3 0.676 0.88 (0.48e1.61)
Pro/Pro 31 5.9 5 9.3 0.393 1.55 (0.56e4.28)
0.915a 0.97 (0.55e1.70)a
0.329b 1.63 (0.61e4.38)b
Arg allele 793 75.4 80 74.1 Ref.
Pro allele 259 24.6 28 25.9 0.765 1.07 (0.66e1.72)
Abbreviations: CI, confidence interval; OR, odds ratio; Ref., reference value.
a Pro/Pro þ Arg/Pro genotype frequencies vs. Arg/Arg genotype.
b Pro/Pro genotype frequency vs. Arg/Arg þ Arg/Pro genotypes.
c Types I, II, III, and IV in the WHO classification [1].
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harboring the Pro allele (P5 0.044). No statistical difference
was observed in the 10-year analysis (data not shown).
4. Discussion
Genetic polymorphisms are known to play a role on can-
cer susceptibility, and their role on glioma risk is starting to
be evaluated [7]. In particular, polymorphisms involved in
DNA repair enzymes (e.g., PRKDC, alias XRCC7; ERCC1,
ERCC2), growth factors (e.g., EGF ), immune response
(IL4 and IL13), and metabolism (e.g., GSTT1) have been
associated with glioma susceptibility [7,26,28e31].
In the present study, we evaluated the role of Arg72Pro
polymorphism of the TP53 gene in susceptibility to devel-
oping glioma in a Portuguese population. The results
showed no significant difference in the genotypic and
allelic frequencies between gliomas and controls, and no
significant association was detected between the genotypeand allele distributions and tumor histological type. These
findings are in agreement with previous reports in gliomas
from distinct geographic regions [21,22,24,32]. At variance
with these results, Parhar et al. [23], reported a significant
association between the Arg/Pro genotype and an increased
risk for high-grade astrocytic tumors. These authors also
found a significant difference in Arg/Pro genotype
distribution between high-grade astrocytic tumors and non-
astrocytic tumors, including oligodendroglial and oligoas-
trocytic tumors [23]. In the present study, we found no
differences between these type of tumors. Notably, Malmer
et al. [25] recently found that the Arg72Pro polymorphism
alone had no impact on glioma risk, but in combination
with two other single-nucleotide polymorphisms of TP53
gene (one at the promoter and the other in intron 6) there
was an association of risk haplotypes and protective haplo-
types in the TP53 gene for glioblastomas [25].
Several explanations can be offered for the discrepancies
observed. (1) The populations analyzed were different.
Beckman et al. [33] were the first to note a significant
18 V. Lima-Ramos et al. / Cancer Genetics and Cytogenetics 180 (2008) 14e19difference in the allelic distribution of Arg72Pro variants
among Nigerian and Swedish populations, and subsequent
studies showed that latitude could explain different allelic
population frequencies [34]. Siddique et al. [35] found
a preferential expression of either Arg72 or Pro72 allele
variants, depending on the ethnicity of the population. (2)
The DNA source (peripheral blood lymphocyte or tumor
tissue) used in the studies was different. If tumor tissue is
used, as in our study, allele retention due to mutation or loss
of heterozygosity cannot be excluded. Nonetheless, the
present findings are not necessarily influenced significantly
by the possible allele retention that may have occurred in
few of our cases. (3) Tumor histological stratification
Fig. 2. KaplaneMeier survival curves of glioma tumor patients treated
with adjuvant therapy (n 5 42) as a function of TP53 codon 72 genotypes
(P 5 0.027).
Fig. 1. KaplaneMeier survival curves of glioma tumor patients (n 5 117)
as a function of TP53 codon 72 genotypes (P 5 0.968).among studies was not uniform. (4) The contribution of en-
vironmental factors, which independently or together with
gene interaction can modulate tumor risk, is usually disre-
garded [36].
In the present study, we also evaluated the role of the
TP53 Arg72Pro polymorphism in the overall survival of
glioma patients. The evaluation did not show any statisti-
cally significant difference in overall survival among the in-
dividuals with different genotypes. When we analyzed the
survival time of patients submitted to adjuvant therapy,
however, we found that the patients harboring the Pro allele
(Arg/ProþPro/Pro) had a significantly better response. This
is at variance with results in other malignancies, such as
head and neck, lung, breast, and ovarian cancer, for which
a better outcome was seen in patients harboring the Arg
allele who received adjuvant therapy [19,37e39]. A recent
study showed that, under hypoxic conditions, cancer cells
harboring the Pro allele had a survival disadvantage com-
pared with cells harboring the Arg allele [40]. Notably,
TP53 Arg72Pro polymorphisms might play a role in the
microenvironment severe hypoxia that characterizes
gliomas [41].
In conclusion, this is the first analysis of TP53 Arg72Pro
polymorphism in Portuguese gliomas. We did not observe
an association of TP53 Arg72Pro polymorphism with gli-
oma risk and overall patient survival. A significant associ-
ation was, however, observed in glioma patient response to
adjuvant therapy. Further studies are warranted to elucidate
the role of this polymorphism in combination with other ge-
netic variants of TP53 gene and additional cancer-related
genes, and to clarify the association of TP53 Arg72Pro with
response of glioma patients to adjuvant therapy.
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